Intestinal Research

IBD
First aid with color atlas for the use of intestinal ultrasound for inflammatory bowel disease in daily clinical practice: Jun Miyoshi, Hiromu Morikubo, Hiromi Yonezawa, Hideaki Mori, Tadakazu Hisamatsu; Intest Res. 2023;21(2):177-188. Published online April 28, 2023; DOI: https://doi.org/10.5217/ir.2023.00003
Web of Science 2 Crossref 2; Full text PubReader ePub PDF

Are the risks of colorectal cancer and biliary cancer really increased if patients with ulcerative colitis have primary sclerosing cholangitis?: Jung Wook Lee, Won Moon; Intest Res. 2023;21(2):171-173. Published online April 28, 2023; DOI: https://doi.org/10.5217/ir.2023.00049; Full text PubReader ePub PDF

The role and prospect of tofacitinib in patients with ulcerative colitis: Jun Lee; Intest Res. 2023;21(1):168-169. Published online November 14, 2022; DOI: https://doi.org/10.5217/ir.2022.00098; Full text PubReader ePub PDF

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis: Jae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, John R Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R Moschen, Neeraj Narula, Grazyna Rydzewska, Axel U Dignass, Simon PL Travis; Intest Res. 2023;21(1):161-167. Published online April 18, 2022; DOI: https://doi.org/10.5217/ir.2022.00006
Crossref 1; Full text PubReader ePub PDF Supplementary Material

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study: Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye, on behalf of the Korean Association for the Study of Intestinal Diseases; Intest Res. 2023;21(1):137-147. Published online July 12, 2022; DOI: https://doi.org/10.5217/ir.2021.00173
Web of Science 2 Crossref 2; Full text PubReader ePub PDF

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial: Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe; Intest Res. 2023;21(1):110-125. Published online March 11, 2022; DOI: https://doi.org/10.5217/ir.2021.00143
Web of Science 10 Crossref 9; Full text PubReader ePub PDF Supplementary Material

Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice: Kun-Yu Tsai, Jeng-Fu You, Tzong-Yun Tsai, Yih Jong Chern, Yu-Jen Hsu, Shu-Huan Huang, Wen-Sy Tsai; Intest Res. 2023;21(1):100-109. Published online November 14, 2022; DOI: https://doi.org/10.5217/ir.2021.00110
Web of Science 1 Crossref 1; Full text PubReader ePub PDF

Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis: Katsuyoshi Matsuoka, Kanae Togo, Noritoshi Yoshii, Masato Hoshi, Shoko Arai; Intest Res. 2023;21(1):88-99. Published online March 11, 2022; DOI: https://doi.org/10.5217/ir.2021.00154
Web of Science 4 Crossref 3; Full text PubReader ePub PDF Supplementary Material

Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis: Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Intest Res. 2023;21(1):61-87. Published online May 31, 2022; DOI: https://doi.org/10.5217/ir.2022.00007
Web of Science 17 Crossref 18; Full text PubReader ePub PDF Supplementary Material

Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease: Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Intest Res. 2023;21(1):43-60. Published online October 18, 2022; DOI: https://doi.org/10.5217/ir.2022.00029
Web of Science 15 Crossref 15; Full text PubReader ePub PDF

Urinary chitinase 3-like 1 and intestinal fatty-acid binding proteins are not elevated in children with inflammatory bowel disease: Shaun Siong Chung Ho, Jacqueline Ilene Keenan, Andrew Stewart Day; Intest Res. 2022;20(4):509-513. Published online July 22, 2022; DOI: https://doi.org/10.5217/ir.2022.00064; Full text PubReader ePub PDF

Novel inflammatory bowel disease (IBD) specific electronic medical record allows scalable auditing of IBD severity, therapy and complications to show the current unmet need in IBD care: Alex Barnes, David Carter, Patricia Kaazan, Alissa Walsh, Susan Connor, Jane M Andrews; Intest Res. 2022;20(4):506-508. Published online April 26, 2022; DOI: https://doi.org/10.5217/ir.2022.00003; Full text PubReader ePub PDF

Abdominal aortic calcification in patients with inflammatory bowel disease: does anti-tumor necrosis factor α use protect from chronic inflammation-induced atherosclerosis?: Aikaterini Mantaka, Nikolaos Galanakis, Dimitrios Tsetis, Ioannis E. Koutroubakis; Intest Res. 2022;20(4):495-505. Published online August 8, 2022; DOI: https://doi.org/10.5217/ir.2022.00017
Web of Science 3 Crossref 3; Full text PubReader ePub PDF

Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study: Masaaki Usami, Ichiro Takeuchi, Reiko Kyodo, Yuri Hirano, Kosuke Kashiwagi, Hiroki Fujikawa, Hirotaka Shimizu, Toshinao Kawai, Katsuhiro Arai; Intest Res. 2022;20(4):475-481. Published online June 13, 2022; DOI: https://doi.org/10.5217/ir.2021.00142
Web of Science 4 Crossref 3; Full text PubReader ePub PDF

Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies: Haruka Otake, Satohiro Matsumoto, Hirosato Mashima; Intest Res. 2022;20(4):464-474. Published online March 31, 2022; DOI: https://doi.org/10.5217/ir.2021.00139
Web of Science 4 Crossref 4; Full text PubReader ePub PDF

IBD